UCB’s drug can be self-administered by patients ... estimating 2026 sales of $376 million and $349 million, respectively. Zilucoplan has also been recommended for approval in the EU, with ...

In 2023, the FDA approved Rystiggo (pipeline candidate: rozanolixizumab-noli) and Zilbrysq (pipeline candidate: zilucoplan) for the treatment of adults with generalized myasthenia gravis.

Rystiggo is just one of the gMG therapies in development at UCB, however, and in September the Belgian biopharma company also got a positive opinion from the CHMP for zilucoplan, a once-daily C5 ...

Four potential treatments being trailed by Biohaven, Prilenia Therapeutics, Clene Nanomedicine and UCB for amyotrophic lateral sclerosis (ALS) have fallen short of their endpoints as part of a US ...

Sabrina Paganoni et al, Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis, JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2024.59058 Verdiperstat in Amyotrophic Lateral ...